Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, As a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Next Previous
Trial Profile

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, As a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elraglusib (Primary) ; Carboplatin; Doxorubicin; Gemcitabine; Irinotecan; Lomustine; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Anaplastic astrocytoma; Appendiceal cancer; Astrocytoma; CNS cancer; Colorectal cancer; Glioblastoma; Glioma; Haematological malignancies; Liver cancer; Male breast cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Oesophageal cancer; Oligodendroglioma; Pancreatic cancer; Pancreatic ductal carcinoma; Parotid cancer; Peritoneal cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms Actuate 1801
  • Sponsors Actuate Therapeutics

Most Recent Events

  • 24 Jun 2025 According to an Actuate Therapeutics media release, the company has highlighted significant and sustained survival benefits through a pre-specified subgroup analysis of its Phase 2 (Actuate-1801 Part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic adenocarcinoma (mPDAC). Along with this, data showing OS benefits across key subgroups is also presented.
  • 24 Jun 2025 Results presented in the Actuate Therapeutics Media Release.
  • 20 Jun 2025 Results presented in the Actuate Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top